RATINGS |
Rating CashFlow: |
Strong Buy
|
|
Return On Equity: |
Neutral
|
|
Return On Asset: |
Neutral
|
|
DE: |
Neutral
|
|
P/E: |
Strong Sell
|
|
Price To Book: |
Strong Buy
|
|
QUARTER GROWTHS |
|
2/20 | 3/20 | 4/20 | 1/21 | 2/21 | 3/21 |
Revenue | | | | | | |
Gr.Profit | | | | | | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE 0 | sector: PE -3.05
|
PE RATIO: COMPANY / INDUSTRY |
N/A
|
Company: PE 0 | industry: PE 5.88
|
DISCOUNTED CASH FLOW VALUE |
N/A
|
N/A
|
Expected Trading Range (DAY) |
$ 176.11 - 181.39
( +/- 1.48%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2021-11-19 | Zakrzewski Joseph S | Sell | 34 499 | Common Stock |
2021-11-19 | Zakrzewski Joseph S | Sell | 10 000 | Option to Purchase Common Stock |
2021-11-19 | Zakrzewski Joseph S | Sell | 7 500 | Option to Purchase Common Stock |
2021-11-19 | Zakrzewski Joseph S | Sell | 7 500 | Option to Purchase Common Stock |
2021-11-19 | Zakrzewski Joseph S | Sell | 10 000 | Option to Purchase Common Stock |
INSIDER POWER |
0.00
|
Last
100 transactions |
Buy:
155 406 | Sell:
743 673 |
Forecast:
01:40 - $184.41
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$178.75 (0.00% )
|
Volume |
7.88 mill
|
Avg. Vol. |
1.265 mill
|
% of Avg. Vol |
623.11 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For XLRN
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.